Hospira – Recall of dextrose 25% injection

- On April 21, 2017, the FDA announced a hospital/user level recall of one lot of Hospira's dextrose 25% injection due to the presence of human hair found within an internal sample syringe.
- The recalled lot was distributed from February 2016 through October 2016.

Product Description	NDC #	Lot # (Expiration date)
Dextrose 25% injection, 2.5 grams (250 mg/mL), 10 mL single-dose prefilled syringe	0409-1775-10	58382EV (10/1/2017)

- Dextrose 25% injection is indicated in the treatment of acute symptomatic episodes of hypoglycemia in the neonate or older infant to restore depressed blood glucose levels and control symptoms.
- Intravenous (IV) administration of particulate to a patient could result in local swelling, irritation of blood vessels or tissue, blockage of blood vessels and/or systemic allergic response to the particulate. IV administration of particulate could also result in localized phlebitis, pulmonary emboli, pulmonary granulomas, immune system dysfunction, pulmonary dysfunction, and pulmonary infarction.
- To date, Hospira has not received reports of any adverse events associated with this issue for the recalled lot.
- Healthcare providers, distributors, wholesalers, and patients should immediately check inventory, quarantine, discontinue use and distribution, and return all recalled product.
- Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to using the recalled product.
- For questions regarding this recall, contact Stericycle at **1-888-570-1678**.
- For any clinical inquiries regarding this recall, contact Pfizer (Hospira is a Pfizer company) at 1**-800-615-0187**.